NMRD (Nemaura Medical) LT-Debt-to-Total-Asset: 0.00 (As of Dec. 2023)


What is Nemaura Medical LT-Debt-to-Total-Asset?

Nemaura Medical NMRD LT-Debt-to-Total-Asset is 0.00 as of Dec. 2023.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Nemaura Medical's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.00.

Nemaura Medical's long-term debt to total assets ratio declined from Dec. 2022 (0.66) to Dec. 2023 (0.00). It may suggest that Nemaura Medical is progressively becoming less dependent on debt to grow their business.

Nemaura Medical  (OTCPK:NMRD) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Nemaura Medical LT-Debt-to-Total-Asset Related Terms

Nemaura Medical LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Nemaura Medical's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nemaura Medical LT-Debt-to-Total-Asset Chart

Nemaura Medical Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.54 0.00 0.21

Nemaura Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.66 0.21 0.01 0.38 0.00

Nemaura Medical LT-Debt-to-Total-Asset Calculation

Nemaura Medical's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

LT Debt to Total Assets (A: Mar. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2023 )/Total Assets (A: Mar. 2023 )
=3.088/14.563
=0.21

Nemaura Medical's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )/Total Assets (Q: Dec. 2023 )
=0/5.169
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Nemaura Medical (NMRD) has a LT-Debt-to-Total-Asset of 0.00 as of Dec. 2023. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Nemaura Medical and its competitors.
Is Nemaura Medical's LT-Debt-to-Total-Asset too high?
Nemaura Medical's current LT-Debt-to-Total-Asset is 0.00.
How does Nemaura Medical's LT-Debt-to-Total-Asset compare to THMO and MOTS?
Nemaura Medical's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?
A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Nemaura Medical and its competitors. Nemaura Medical's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nemaura Medical stock overvalued right now?
Nemaura Medical (NMRD) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Nemaura Medical (NMRD), the current LT-Debt-to-Total-Asset is 0.00 as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nemaura Medical Business Description

Address 57 West 57th Street, New York, NY, USA, 10019
Nemaura Medical Inc is a medical technology company developing sugarBEAT as a non-invasive, affordable, and flexible Continuous Glucose Monitor (CGM) designed for people with diabetes and pre-diabetics to manage their glucose levels. Insulin users can adjunctively use sugarBEAT when calibrated with a finger-stick glucose reading. SugarBEAT consists of a daily disposable adhesive skin patch connected to a rechargeable transmitter with an app displaying glucose readings at five-minute intervals for periods up to 24 hours.